RIGL Stock News & Catalysts – Rigel Pharmaceuticals

FEATURED

Rigel Reports Third Quarter 2026 Financial Results

Third quarter 2026 total revenues of $80.9 million, including net product sales of $72.3 million and contract revenues from collaborations of $8.6 million, and net income of $13.2 millionVEPPANU™ (vepdegestrant) became

Summary

Nov 5, 2026, 4:01 PM ·PRNewswire

RECENT

Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

Oral presentation to feature updated data from the dose escalation and dose expansion phases of the ongoing Phase 1b study evaluating R289, Rigel's dual IRAK1/4 inhibitor, in patients with relapsed or refractory

Nov 4, 2026, 9:15 AM ·PRNewswire

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its third quarter 2026 financial results after market close on Thursday, November

Oct 29, 2026, 8:05 AM ·PRNewswire

Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026

Pooled ARROW and TAPISTRY analysis demonstrated a 53% overall response rate in patients with RET fusion-positive solid tumorsAdditional analyses highlight first-line clinical outcomes and patient-reported quality of

Oct 19, 2026, 8:05 AM ·PRNewswire

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement

Oct 2, 2026, 8:05 AM ·PRNewswire

Rigel to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean

Sep 2, 2026, 8:05 AM ·PRNewswire

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBCSOUTH SAN FRANCISCO, Calif., Aug. 11, 2026

Aug 13, 2026, 8:05 AM ·PRNewswire

Rigel Reports Second Quarter 2026 Financial Results

Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations of $11.7 million, and net income of $17.3 millionExpanded commercial portfolio

Aug 4, 2026, 4:01 PM ·PRNewswire

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its second quarter 2026 financial results after market close on Tuesday, August 4,

Jul 28, 2026, 8:05 AM ·PRNewswire

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (NASDAQ:RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement

Jul 7, 2026, 8:05 AM ·PRNewswire

Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer

Dr. Hannah has decades of oncology drug development experience and has served on Rigel's Board of Directors since 2021 She has resigned from Rigel's Board of Directors to join the companySOUTH SAN FRANCISCO,

Jul 1, 2026, 8:05 AM ·PRNewswire

Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)

SOUTH SAN FRANCISCO, Calif., June 16, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the closing of

Jun 16, 2026, 4:01 PM ·PRNewswire

Rigel to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul

May 27, 2026, 8:05 AM ·PRNewswire

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLCFinal

May 21, 2026, 5:17 PM ·PRNewswire

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean

May 14, 2026, 8:05 AM ·PRNewswire

Rigel Pharmaceuticals, Inc. RIGL · News